MF
NBIX icon

Magnetar Financial’s Neurocrine Biosciences NBIX Stock Holding History

Magnetar Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$451K Buy
+2,674
New +$397K ﹤0.01% 642
2026
Q1 		– Sell
-29,192
Closed -$4.14M – 1304
2025
Q4 		$4.14M Sell
29,192
-4,879
-14% -$707K 0.04% 221
2025
Q3 		$4.78M Buy
+34,071
New +$4.62M 0.03% 239
2025
Q2 		– Sell
-9,935
Closed -$1.1M – 1047
2025
Q1 		$1.1M Buy
+9,935
New +$1.26M 0.01% 327
2024
Q4 		– Sell
-2,732
Closed -$315K – 730
2024
Q3 		$315K Buy
+2,732
New +$375K 0.01% 398
2020
Q4 		– Sell
-19,009
Closed -$1.83M – 837
2020
Q3 		$1.83M Buy
+19,009
New +$2.2M 0.03% 266
2020
Q1 		– Sell
-2,491
Closed -$268K – 577
2019
Q4 		$268K Buy
+2,491
New +$261K 0.01% 459

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Magnetar Financial's NBIX Position: Q2 2026 in Review

Magnetar Financial opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 2,674 shares worth $451K. The stake represents ﹤0.01% of the portfolio and ranks #642 among its holdings. This is a return to the name: Magnetar Financial previously reported a position in NBIX as recently as Q4 2025.

Magnetar Financial first reported a position in NBIX in Q4 2019 and has held it in 7 quarters since. The position peaked at $4.78M in Q3 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Magnetar Financial held 2,674 shares of Neurocrine Biosciences worth $451K as of Q2 2026.
  • Neurocrine Biosciences was a new Magnetar Financial position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Magnetar Financial's portfolio in Q2 2026, its #642 holding.
  • Magnetar Financial first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 7 quarters since.
  • Magnetar Financial's Neurocrine Biosciences position peaked at $4.78M in Q3 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Magnetar Financial's 13F filing for Q2 2026, filed 14 Aug 2026.